Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
出版年份 2020 全文链接
标题
Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
作者
关键词
-
出版物
Scientific Reports
Volume 10, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-09-01
DOI
10.1038/s41598-020-71263-9
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- PEOPLE: PatiEnt prOstate samPLes for rEsearch, a tissue collection pathway utilizing MRI data to target tumor and benign tissue in fresh radical prostatectomy specimens
- (2019) Susan Heavey et al. PROSTATE
- Anti‐tumor effects of PIM / PI 3K/ mTOR triple kinase inhibitor IBL ‐302 in neuroblastoma
- (2019) Sofie Mohlin et al. EMBO Molecular Medicine
- Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking
- (2019) Susan Heavey et al. Jove-Journal of Visualized Experiments
- Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer
- (2019) Tom Malone et al. PHARMACOLOGY & THERAPEUTICS
- Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers
- (2018) Jorge Cortes et al. BRITISH JOURNAL OF CANCER
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016
- (2018) et al. JAMA Oncology
- Mechanisms behind resistance to PI3K Inhibitor treatment induced by the PIM kinase
- (2018) Jin H. Song et al. MOLECULAR CANCER THERAPEUTICS
- PI3K pathway in prostate cancer: All resistant roads lead to PI3K
- (2018) Soonbum Park et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing
- (2018) Sadakatsu Ikeda et al. CANCER BIOLOGY & THERAPY
- PRAS40 signaling in tumor
- (2017) Dan Lv et al. Oncotarget
- FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway
- (2017) Keigo Okada et al. Oncotarget
- The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition
- (2017) Luca Mologni et al. Journal of Cancer
- The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
- (2016) Jennifer L. Hsu et al. CANCER AND METASTASIS REVIEWS
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC
- (2016) Susan Heavey et al. Oncotarget
- The role of PIM1/PIM2 kinases in tumors of the male reproductive system
- (2016) Manuel Pedro Jiménez-García et al. Scientific Reports
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- PIM kinase (and Akt) biology and signaling in tumors
- (2015) Noel A. Warfel et al. PHARMACOLOGY & THERAPEUTICS
- Pim Kinases Promote Migration and Metastatic Growth of Prostate Cancer Xenografts
- (2015) Niina M. Santio et al. PLoS One
- Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study
- (2015) H. Ross-Adams et al. EBioMedicine
- PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
- (2014) AndrewC Hsieh et al. ASIAN JOURNAL OF ANDROLOGY
- Strategic targeting of the PI3K–NFκB axis in cisplatin-resistant NSCLC
- (2014) Susan Heavey et al. CANCER BIOLOGY & THERAPY
- PIM Kinase Inhibitor AZD1208 for Treatment of MYC-Driven Prostate Cancer
- (2014) Austin N. Kirschner et al. JNCI-Journal of the National Cancer Institute
- AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia
- (2013) E. K. Keeton et al. BLOOD
- Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation
- (2013) J. Lu et al. BLOOD
- Elevation of Receptor Tyrosine Kinases by Small Molecule AKT Inhibitors in Prostate Cancer Is Mediated by Pim-1
- (2013) B. Cen et al. CANCER RESEARCH
- Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC
- (2013) Susan Heavey et al. CANCER TREATMENT REVIEWS
- Rational cotargeting of Pim-1 and Akt in prostate cancer
- (2013) Paul Toren et al. Expert Review of Anticancer Therapy
- PIM1 Protein Kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells
- (2010) Fengxue Zhang et al. CANCER BIOLOGY & THERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation